Key result
Female sex was associated with a 60% higher hazard of bleeding compared to males after continuous-flow LVAD implantation (adjusted HR 1.6; 95% CI 1.1-2.2).
Why the study?
Does female sex increase the risk of bleeding complications in patients receiving continuous-flow LVADs compared to male sex?
Cohort (n=375)
No
Does female sex increase the risk of bleeding complications in patients receiving continuous-flow LVADs compared to male sex?
Hazard Ratio: 1.6 (95% CI 1.1–2.2)
Absolute Event Rate: 33% vs 46%
p-value: p=0.027
Female patients receiving continuous-flow LVADs have a 60% higher hazard of bleeding complications compared to males, highlighting the need for sex-specific considerations in device management.
Female sex may confer higher bleeding risk on LVAD; supports sex-specific analyses in future device trials.
The aims of this analysis were to characterize the burden and timing of bleeding events in females versus males on left ventricular assist device (LVAD) support. A single-center retrospective review of 375 patients receiving continuous-flow LVADs was performed. Bleeding events included gastrointestinal, naso-oropharyngeal, gynecologic (GYN), intracranial hemorrhage (ICH), and mediastinal bleeding. Cox hazard ratios (HRs) [95% CI] and incident event rates for females versus males were calculated. Eighty-four females (22%) and 291 males (78%) received an LVAD. There were 189 patients with 406 bleeding events over a median 399 days of support. Two-year freedom from bleeding was 33 ± 6.2% in females and 46 ± 3.7% in males (p = 0.027). Correlates of bleeding included female sex (adjusted HR = 1.6 [1.1-2.2]) and older age (adjusted HR = 1.2 [1.1-1.3] per 10 years). There was no sex-associated difference in 30 day mediastinal bleeding (males 12%; females 16% at 30 days; overall p = 0.35), but incident event rates for overall bleeding and naso-oropharyngeal bleeding were higher in females (p < 0.05) and trends were noted in ICH (eppy: 0.06 male vs. 0.10 female, p = 0.14). Eight females (10%) experienced 12 GYN bleeding events; five required surgical intervention. In summary, females had a 60% higher hazard of bleeding than males with significant morbidity encountered from mucosa (including vaginal) bleeding. Future large device studies should be inclusive of sex-specific outcomes.
No takes yet. Share an insight, caveat, or question.
Yavar et al. (2017) conducted a cohort in Patients receiving continuous-flow left ventricular assist devices (LVADs) (n=375). Female sex vs. Male sex was evaluated on 2-year freedom from bleeding (HR 1.6, 95% CI 1.1-2.2, p=0.027). Female sex was associated with a 60% higher hazard of bleeding compared to males after continuous-flow LVAD implantation (adjusted HR 1.6; 95% CI 1.1-2.2).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: